Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2026, with the report issued on July 28, 2026. The filing announces positive clinical trial results for Ris-Rez (risvutatug rezetecan), a B7-H3-targeted antibody-drug conjugate (ADC), developed by GSK's licensor, Hansoh Pharmaceutical Group Co., Ltd. GSK holds exclusive global rights to develop and commercialize Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on clinical development milestones rather than a financial statement.
Material Changes and Clinical Milestones
- ARTEMIS-011 Trial Success: Hansoh Pharma announced that the pivotal phase III trial (ARTEMIS-011) for Ris-Rez in China met its primary endpoint of progression-free survival (PFS) in patients with relapsed osteosarcoma who had received at least two prior lines of systemic therapy.
- Statistical Significance: Ris-Rez demonstrated statistically significant and clinically meaningful improvements in PFS compared with chemotherapy. Consistent benefits were observed in secondary endpoints, including overall survival.
- Safety Profile: The safety profile was consistent with prior findings, with no new safety signals identified.
- Regulatory Submission: These data will be used by Hansoh Pharma for regulatory submission in China.
Guidance, Outlook, and Management Commentary
Management Commentary: Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D at GSK, stated that these results strengthen confidence in the broad potential of Ris-Rez and validate B7-H3 as a promising target across multiple tumor types, building on recent pivotal data in small-cell lung cancer (SCLC).
Development Outlook:
- GSK is advancing EMBOLD Sarcoma-202, a global phase Ib/II trial of Ris-Rez in previously treated unresectable advanced or metastatic sarcomas, including osteosarcoma.
- The broader clinical development program includes multiple solid tumors, such as lung and prostate cancers.
- Ris-Rez is the only B7-H3-targeted ADC to deliver positive phase III outcomes across multiple tumor types to date.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's 2025 Annual Report on Form 20-F and Q1 2026 Results.
Important Facts for Investor Verification
- Verify the specific magnitude of the PFS improvement and overall survival data in the full clinical study report for ARTEMIS-011.
- Confirm the timeline for Hansoh Pharma's regulatory submission in China and GSK's subsequent filing plans in other jurisdictions.
- Monitor the enrollment and interim data for the global EMBOLD Sarcoma-202 trial.
- Review the commercial agreement terms between GSK and Hansoh Pharma regarding milestone payments and royalties triggered by this phase III success.
- Assess the competitive landscape for B7-H3-targeted therapies in osteosarcoma and SCLC.